- Home
- RDHL vs PRPO Comparison
RDHL vs PRPO Comparison
Compare RDHL & PRPO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | RDHL | PRPO |
|---|---|---|
| Founded | 2009 | N/A |
| Country | Israel | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Laboratory Analytical Instruments |
| Sector | Health Care | Industrials |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.3M | 42.0M |
| IPO Year | 2012 | 2000 |
Fundamental Metrics
Financial Performance| Metric | RDHL | PRPO |
|---|---|---|
| Price | $0.48 | $23.30 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 209.2K | 120.8K |
| Earning Date | 09-30-2026 | 11-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 92.15 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $24,049,000.00 |
| Revenue This Year | $17,592.31 | $233.72 |
| Revenue Next Year | $25.89 | $22.61 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 29.77 |
| 52 Week Low | $0.48 | $16.40 |
| 52 Week High | $2.26 | $33.63 |
Technical Indicators
Market Signals| Indicator | RDHL | PRPO |
|---|---|---|
| Relative Strength Index (RSI) | 34.08 | N/A |
| Support Level | N/A | N/A |
| Resistance Level | $1.07 | N/A |
| Average True Range (ATR) | 0.03 | 0.00 |
| MACD | -0.01 | 0.00 |
| Stochastic Oscillator | 12.97 | 0.00 |
Price Performance
Historical ComparisonAbout RDHL Redhill Biopharma Ltd.
RedHill Biopharma Ltd is a specialty biopharmaceutical company mainly focused on the U.S. development and commercialization of drugs for GI diseases, infectious diseases, and oncology. The Company is mainly focused on the advancement of its development pipeline of clinical-stage therapeutic candidates and also commercializes its GI-related product, Talicia (omeprazole, amoxicillin, and rifabutin) in the U.S. Its therapeutic candidates include opaganib, RHB-204, RHB-104, RHB-102 (Bekinda), and RHB-107.
About PRPO Precipio Inc.
Precipio Inc is a healthcare biotechnology company focused on cancer diagnostics. Its objective is to enhance diagnostic accuracy & accessibility while building a sustainable business model that supports ongoing innovation. The company operates Clinical Laboratory Improvement Amendments laboratories in both New Haven, Connecticut, & Omaha, Nebraska, providing essential blood cancer diagnostics to office-based oncologists in many states nationwide. The company operates in a single segment, which includes two divisions: the Pathology Services Division & the Products Division. The Pathology Services provides specialized cancer diagnostic testing services. The pathology services division specializes in diagnostic testing focused mainly on hematologic cancers.